Pharmaceuticals

Haisco

Haisco released FY2026 Q1 earnings on April 26 During-Market (BJT), actual revenue CNY 1.564 B, actual EPS CNY 0.5

Haisco FY2026 Q1 Earnings Release Scheduled for April 27 During-Market BJT

AbbVie Signs Global Pain Medication License Agreement with Hisun

Haisco released FY2025 Q4 earnings on April 12 After-Market (BJT), actual revenue CNY 1.088 B, actual EPS CNY -0.0309

Haisco released FY2025 earnings on April 12 After-Market (BJT), actual revenue CNY 4.388 B (forecast CNY 4.453 B), actual EPS CNY 0.23 (forecast CNY 0.47)

Haisco to Release FY2025 Annual Earnings on April 13 After-Market (BJT), Forecast Revenue CNY 4.453 B, EPS CNY 0.47

Haisco released FY2025 9 Months Earnings on October 28 Pre-Market (BJT), actual revenue CNY 3.3 B, actual EPS CNY 0.261

Haisco released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue CNY 1.299 B, actual EPS CNY 0.1373

Haisco to Release FY2025 Q3 Earnings on October 29, Pre-Market BJT

Haisco released FY2025 Q2 earnings on August 22 During-Market (BJT), actual revenue CNY 1.109 B, actual EPS CNY 0.0837

Haisco released FY2025 Semi-Annual earnings on August 22 During-Market (BJT), actual revenue CNY 2.001 B, actual EPS CNY 0.12

Haisco to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Hisun Pharmaceutical Receives Approval for HSK47977 Clinical Trials for Non-Hodgkin's Lymphoma

Hisunpharma Announces International Patent Application for PARP Inhibitor

Haisike Initiates Phase III Clinical Trial for HSK21542 Injection

Hiseco's HSK47388 Approved for Clinical Trials

Hisun Pharmaceutical Starts Phase III Clinical Trial for HSK21542 Injection

Haisike's New Drug HSK3486 Receives FDA Acceptance Notice

Huayuan Securities Maintains Buy Rating for Haisike

Haisike Shares Hit 60-Day High and Receive Buy Rating

ABBV

002653

520880

159849

520690

The General Office of the State Council issued new policies aimed at improving the drug pricing mechanism and promoting pharmaceutical innovation. Overseas licensing of domestic innovative drugs continues to grow, with Haisco signing an exclusive licensing agreement with AbbVie worth up to $745 million. Since the beginning of 2026, multiple domestic pharmaceutical companies have reached cooperation agreements with multinational giants, leading to a surge in deal volume and rising transaction values. The industry is shifting from being driven solely by overseas expansion to a dual-drive model involving both domestic and international markets, enhancing sales expectations for innovative drugs, optimizing profit margins across the industrial chain, and strengthening R&D demand

Wallstreetcn

Abbvie

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

CSPC PHARMA

INNOVENT BIO

New Drug Pricing Policy Empowers Innovation; Overseas Licensing Accelerates Dual-Drive Mechanism for the Industry

159859

AbbVie has entered a $745 million deal with Chinese biopharmaceutical company Haisco to enhance its pain pipeline amid global patent expirations. The agreement includes an upfront payment of $30 million and up to $715 million in milestone payments for rights to several pain-related drugs. This move is part of AbbVie's strategy to replenish its portfolio following the anticipated decline in Humira sales. The collaboration reflects a broader trend in the pharmaceutical industry towards securing innovative assets from China, which is emerging as a leader in drug development.

Pharmaceutical Technology

Tianhong CNI BIOMEDICINE ETF

AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid

LABU

SBIO

ARKG

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain | ABBV Stock News

StockTitan

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

iShares US Pharma

VG Health

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain | ABBV Stock News

A dual-target therapy known as HSK39004 is set to enter the competitive global market for Chronic Obstructive Pulmonary Disease (COPD) treatment. This innovative product signifies a focus on international capabilities and advancement. The announcement was made by Haisco Pharmaceutical Group Co., Ltd. on January 9, 2026. The company, identified by Ticker Code 002653, aims to make a significant impact in the field, showcasing their dedication to addressing respiratory issues on a global scale.

Unusual Whales

Haisco grants AirNexis global rights to HSK39004 drug in deal exceeding USD 1 billion, targeting COPD market.

Haisco Pharmaceutical Group has licensed its COPD treatment, HSK39004, to US-based AirNexis Therapeutics for up to USD1.1 billion. AirNexis will develop and commercialize the drug, which is currently in Phase II trials in China. The deal includes an upfront payment of USD108 million and potential milestone payments and royalties. This agreement reflects the growing trend of Chinese innovative drugs entering global markets, with a significant increase in out-licensing deals last year. Haisco's net profit fell 23% in the first nine months of last year, while operating revenue rose 20%.

Yicai

China's Haisco Licenses COPD Drug to AirNexis for Up to USD1.1 Billion

Haisco(002653.SZ)

New Drug Pricing Policy Empowers Innovation; Overseas Licensing Accelerates Dual-Drive Mechanism for the Industry

AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain | ABBV Stock News

Haisco grants AirNexis global rights to HSK39004 drug in deal exceeding USD 1 billion, targeting COPD market.

China's Haisco Licenses COPD Drug to AirNexis for Up to USD1.1 Billion